It has increased rapidly, especially in developing countries that lack controlled antimicrobial policy, and where poor infrastructures enable the flow of AMR genes between the environment, animals and ...

Especially when we consider that the loss in Q4 was very minor, and the company has still been generating positive free cash flow. AMR reported an adjusted EBITDA of $53M in Q4 2024, up 8% ...